Clinical trial
Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer
NCT00003023 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00003023 |
|---|---|
| Title | Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer |
| Official title | Phase I Trial of A1G4 Anti-Idiotypic Monoclonal Antibody With Bacille-Calmette-Guerin (BCG) Adjuvant in High Risk Patients With GD2 Positive Tumors |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neuroblastoma, Sarcoma |
| Intervention type | Biological |
| Interventions | BCG vaccine, monoclonal antibody A1G4 anti-idiotype vaccine |
| Enrollment | 24 |
| Start date | Mar 1, 1997 |
| Primary completion | Jan 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: